我們已在上線！進一步了解

Pliant Therapeutics

PLRX

市值 US$5572萬

0.8999 USD

-0.0725

7.46%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

0.9240

+0.0241

2.68%

1天

-7.46%

5天

-12.63%

1個月

-15.9%

3個月

-18.93%

6個月

-30.78%

今年迄今

-28.01%

1年

-45.46%

5年

-94.65%

10年

-95.78%

關於： Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

員工： 49

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 0%

中性 100%

負面 0%

中性

GlobeNewsWire

16 天前

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise

中性

GlobeNewsWire

上個月

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the potential the treatment of solid tumors that are resistant to immune checkpoint inhibitors (ICIs).

$Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors$

中性

GlobeNewsWire

2 個月前

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D.

中性

GlobeNewsWire

3 個月前

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.

Appointments bring global oncology drug development experience and deepen Board's operational and regulatory expertise

中性

Seeking Alpha

4 個月前

Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

中性

GlobeNewsWire

4 個月前

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.

中性

GlobeNewsWire

5 個月前

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors

中性

GlobeNewsWire

5 個月前

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the 2026 RBC Capital Markets Global Healthcare Conference. Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer, and Keith Cummings, M.D., Pliant's Chief Financial Officer, will participate in a fireside chat on Tuesday, May 19, 2026, at 11:30 a.m. Eastern Time.

中性

GlobeNewsWire

5 個月前

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. PLN-101095 is an oral, small molecule, dual selective inhibitor of the integrins αvβ8 and αvβ1.

$Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors$

中性

GlobeNewsWire

6 個月前

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months

$Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting$

查看新聞排名

價格圖表採用Lightweight Charts™實作

Pliant Therapeutics PLRX 市值 US$5572萬

新聞

Pliant Therapeutics

PLRX

市值 US$5572萬